Last reviewed · How we verify
Clopidogrel treatment
Clopidogrel inhibits platelet aggregation by blocking the P2Y12 adenosine diphosphate receptor on platelets.
Clopidogrel inhibits platelet aggregation by blocking the P2Y12 adenosine diphosphate receptor on platelets. Used for Acute coronary syndrome (unstable angina and non-ST elevation myocardial infarction), ST-elevation myocardial infarction, Peripheral arterial disease.
At a glance
| Generic name | Clopidogrel treatment |
|---|---|
| Sponsor | VA Office of Research and Development |
| Drug class | P2Y12 receptor antagonist / Thienopyridine antiplatelet agent |
| Target | P2Y12 receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Clopidogrel is a thienopyridine prodrug that requires hepatic metabolism to its active form. The active metabolite irreversibly binds to the P2Y12 receptor on platelet surfaces, preventing ADP-induced platelet activation and aggregation. This antiplatelet effect reduces thrombotic events in patients at risk for cardiovascular complications.
Approved indications
- Acute coronary syndrome (unstable angina and non-ST elevation myocardial infarction)
- ST-elevation myocardial infarction
- Peripheral arterial disease
- Cerebrovascular disease / recent stroke or transient ischemic attack
- Secondary prevention of atherothrombotic events
Common side effects
- Bleeding
- Dyspepsia
- Diarrhea
- Rash
- Thrombotic thrombocytopenic purpura (TTP)
- Neutropenia
Key clinical trials
- The Effect and Safety of Combined Anti-platelet Treatment in Acute Ischemic Stroke Due to Large Artery Atherosclerosis (PHASE4)
- Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure (PHASE4)
- PFO Closure, Oral Anticoagulants or Antiplatelet Therapy After PFO-associated Stroke in Patients Aged 60 to 80 Years (PHASE3)
- Precision Reperfusion Therapy for Disabling Minor Stroke With Large Vessel Occlusion Beyond Time Window (PHASE3)
- INdobufen Versus asPirin in Endovascular Unruptured Intracranial Aneurysms Treatment (INPUT) (NA)
- Effect of ZaStaprazan on Platelet Reactivity of Clopidogrel After PercuTaneous CoronAry InteRvention (PHASE4)
- Combination Antithrombotic Treatment for Prevention of Recurrent Ischemic Stroke in IntraCranial Atherosclerotic diseaSe (CATIS- ICAS) (PHASE3)
- Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Clopidogrel treatment CI brief — competitive landscape report
- Clopidogrel treatment updates RSS · CI watch RSS
- VA Office of Research and Development portfolio CI